DNTH
Dianthus Therapeutics, Inc. · Healthcare · Market cap $4.4B
Insiders sold $29.3M net in the last 90 days ·7 sellers, 0 buyers· 9 of 9 sales under Rule 10b5-1 plans· latest Form 4 filed Sep 18, 2026
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$71.2M
reported sales (SEC code S)
Unique Insiders
8
in the rolling window
Latest filing
Sep 18, 2026
CARR EDWARD
Dianthus Therapeutics, Inc. (DNTH) has 22 SEC Form 4 filings (107 transaction rows) in the rolling window, disclosed by 8 distinct insiders. Most recent filing: Sep 18, 2026.
Inside the rolling window, 8 insiders at Dianthus Therapeutics, Inc. reported no open-market purchases and 22 open-market sales totaling $71.2M. The most active filer is EVP, Head of R&D Randhawa Simrat with 5 filings. Insiders have net sold $46.6M over the trailing 6 months. The most recent open-market filing is a sale of 20,000 shares by CHIEF ACCOUNTING OFFICER CARR EDWARD, dated Sep 17, 2026, worth $2.0M.
- Industry:Biotechnology
- CEO:Marino Garcia
- Employees:92
- HQ:New York, NY, US
- IPO:2018-06-21
| Source | |||||||
|---|---|---|---|---|---|---|---|
CARR EDWARDFirst in 6 months | CHIEF ACCOUNTING OFFICER | Sale | 20,000 | $2.0M | Sep 18 | -19.3% | SEC ↗ |
Randhawa SimratFirst in 3 months | EVP, Head of R&D | Sale | 23,124 | $2.5M | Sep 3 | -27.6% | SEC ↗ |
| Director | Sale | 2,778 | $327K | Aug 19 | -31.3% | SEC ↗ | |
McGeorge AnneFirst filing | Director | Sale | 7,750 | $845K | Aug 11 | -28.0% | SEC ↗ |
Read SimonFirst filing | Director | Sale | 2,777 | $304K | Aug 11 | — | SEC ↗ |
| SVP, General Counsel and Sec. | Sale | 3,833 | $424K | Aug 11 | — | SEC ↗ | |
| SVP, General Counsel and Sec. | Sale | 16,167 | $1.8M | Aug 11 | — | SEC ↗ | |
Garcia MarinoFirst in 5 months | CEO AND PRESIDENT | Sale | 166,000 | $17.9M | Aug 7 | — | SEC ↗ |
Savitz RyanFirst in 3 months | EVP, CFO & CBO | Sale | 31,249 | $3.2M | Jul 13 | — | SEC ↗ |
Veness Adam MFirst filing | SVP, General Counsel and Sec. | Sale | 30,000 | $2.4M | Jun 18 | — | SEC ↗ |
| EVP, Head of R&D | Sale | 26,530 | $2.4M | Jun 2 | — | SEC ↗ | |
| Director | Sale | 599 | $51K | May 11 | — | SEC ↗ | |
| EVP, CFO & CBO | Sale | 8,224 | $739K | Apr 10 | — | SEC ↗ | |
Savitz RyanFirst in 4 months | EVP, CFO & CBO | Sale | 114,367 | $9.5M | Apr 1 | — | SEC ↗ |
| Director | Sale | 599 | $48K | Apr 1 | — | SEC ↗ | |
Soteropoulos PaulaFirst filing | Director | Sale | 27,594 | $2.2M | Mar 26 | — | SEC ↗ |
CARR EDWARDFirst filing | CHIEF ACCOUNTING OFFICER | Sale | 43,682 | $3.6M | Mar 13 | — | SEC ↗ |
Garcia MarinoFirst filing | CEO AND PRESIDENT | Sale | 122,918 | $10.0M | Mar 13 | — | SEC ↗ |
Randhawa SimratFirst in 4 months | EVP, Head of R&D | Sale | 33,830 | $2.8M | Mar 13 | — | SEC ↗ |
Savitz RyanFirst filing | CFO & CBO | Sale | 20,000 | $904K | Dec 5 | — | SEC ↗ |
Randhawa SimratFirst filing | EVP, Head of R&D | Sale | 87,507 | $3.2M | Nov 14 | — | SEC ↗ |
Randhawa SimratFirst filing | EVP, Head of R&D | Sale | 109,031 | $4.2M | Nov 14 | — | SEC ↗ |
Earnings: last 7 quarters
Frequently asked questions
How many SEC Form 4 insider filings does DNTH have?
Dianthus Therapeutics, Inc. (DNTH) has 22 SEC Form 4 filings (107 transaction rows) in the rolling 365-day window, disclosed by 8 distinct insiders. Most recent filing: Sep 18, 2026.
When was the most recent SEC Form 4 filing for DNTH?
The most recent Form 4 filing for DNTH on Tracefour is dated Sep 18, 2026.
Who is the most active insider at DNTH?
The most active SEC Form 4 filer at DNTH in the rolling window is EVP, Head of R&D Randhawa Simrat, with 5 filings.
What is the net insider flow at DNTH over the last 6 months?
Over the trailing 180 days, insiders at DNTH have net sold $46.6M based on SEC Form 4 disclosures.
What is the total insider buy and sell value at DNTH in the current window?
Inside the rolling window, insiders at DNTH bought $0 and sold $71.2M based on SEC Form 4 filings.
Can I get alerts for DNTH insider trading?
Yes. Tracefour sends a free email when a new SEC Form 4 purchase or sale is filed at Dianthus Therapeutics, Inc. (DNTH). Alerts are set per company from the page itself, there is no paid tier, and each email links to the original filing on SEC EDGAR.
Related companies
Dianthus Therapeutics, Inc. is in the Healthcare sector.